0.83%
9.53%
-9.99%
-14.78%
-9.73%
25.04%
25.59%
AI Spotlight on AMGN
Company Description
Amgen Inc.discovers, develops, manufactures, and delivers human therapeutics worldwide.It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.
The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA.Amgen Inc.
serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc.
to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer.It has an agreement with Kyowa Kirin Co., Ltd.to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc.
and Plexium, Inc.Amgen Inc.was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Market Data
| Last Price | 284.02 |
| Change Percentage | 0.83% |
| Open | 284.81 |
| Previous Close | 281.68 |
| Market Cap ( Millions) | 152670 |
| Volume | 2554991 |
| Year High | 346.85 |
| Year Low | 253.3 |
| M A 50 | 273.05 |
| M A 200 | 304.23 |
Financial Ratios
| FCF Yield | 4.12% |
| Dividend Yield | 3.17% |
| ROE | 68.49% |
| Debt / Equity | 802.42% |
| Net Debt / EBIDTA | 393.77% |
| Price To Book | 20.26 |
| Price Earnings Ratio | 36.06 |
| Price To FCF | 24.3 |
| Price To sales | 4.71 |
| EV / EBITDA | 15.64 |
News
- Jan -29 - Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?
- Jan -28 - Amgen (AMGN) Stock Dips While Market Gains: Key Facts
- Jan -25 - 5 Best CEFs This Month For Nearly 10% Yield (January 2025)
- Jan -25 - These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
- Jan -23 - Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
- Jan -21 - Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
- Jan -20 - Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
- Jan -17 - Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
- Jan -17 - FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
- Jan -17 - US FDA approves Amgen's colorectal cancer therapy
- Jan -16 - 2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
- Jan -14 - Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
- Jan -14 - Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
- Jan -14 - Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
- Jan -13 - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
- Jan -13 - 3 High-Yield Dividend Stocks to Buy in 2025
- Jan -08 - AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
- Jan -08 - Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
- Jan -08 - Amgen (AMGN) Advances While Market Declines: Some Information for Investors
- Jan -07 - Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Human Therapeutics
Expected Growth : 4.5 %
What the company do ?
Human Therapeutics from Amgen Inc. develops innovative medicines to treat serious diseases, improving lives of millions worldwide.
Why we expect these perspectives ?
Amgen's Human Therapeutics segment growth is driven by strong demand for its flagship products, including Enbrel and Prolia, as well as increasing adoption of newer launches such as Repatha and Aimovig. Additionally, the company's focus on innovation, strategic partnerships, and expansion into emerging markets contribute to its 4.5% growth.
Segment n°2 -> Other
Expected Growth : 3.5 %
What the company do ?
Other from Amgen Inc. refers to the revenue generated from licensing and collaboration agreements, and sales of certain products.
Why we expect these perspectives ?
Amgen's 'Other' segment, with 3.5% growth, is driven by increasing sales of biosimilar products, particularly MVASI and KANJINTI, as well as growing demand for Neulasta Onpro, a long-acting formulation of pegfilgrastim. Additionally, the segment benefits from the company's strategic partnerships and collaborations, such as the Novartis biosimilar agreement.
Amgen Inc. Products
| Product Range | What is it ? |
|---|---|
| Enbrel | A prescription medication used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. |
| Neulasta | A prescription medication used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. |
| Prolia | A prescription medication used to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. |
| Xgeva | A prescription medication used to prevent skeletal-related events in patients with bone metastases from solid tumors. |
| Vectibix | A prescription medication used to treat metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors. |
| Nplate | A prescription medication used to treat thrombocytopenia (low platelet count) in patients with chronic immune thrombocytopenia (ITP). |
| Aranesp | A prescription medication used to treat anemia in patients with chronic kidney disease (CKD) and in patients with cancer undergoing chemotherapy. |
| EPOGEN | A prescription medication used to treat anemia in patients with chronic kidney disease (CKD) and in patients with cancer undergoing chemotherapy. |
| Neupogen | A prescription medication used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. |
Amgen Inc.'s Porter Forces
Threat Of Substitutes
Amgen Inc. faces moderate threat from substitutes due to the presence of alternative treatments and therapies for various diseases.
Bargaining Power Of Customers
Amgen Inc. has a diverse customer base, which reduces the bargaining power of individual customers, giving the company an upper hand in negotiations.
Bargaining Power Of Suppliers
Amgen Inc. relies on a few key suppliers for raw materials and services, giving them some bargaining power, but the company's size and scale mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with Amgen Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share, leading to intense rivalry among companies like Amgen Inc.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 91.20% |
| Debt Cost | 5.20% |
| Equity Weight | 8.80% |
| Equity Cost | 6.94% |
| WACC | 5.36% |
| Leverage | 1036.79% |
Amgen Inc. : Quality Control
Amgen Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
| ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
AbbVie
A-Score
1-Year Total Return ->
🥉
Gilead Sciences
A-Score
1-Year Total Return ->
4
Merck
A-Score
1-Year Total Return ->
5
J&J
A-Score
1-Year Total Return ->
6
